336 related articles for article (PubMed ID: 25185990)
1. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
Prudkin L; Nuciforo P
Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
[TBL] [Abstract][Full Text] [Related]
2. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
3. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
4. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials.
Yee LM; McShane LM; Freidlin B; Mooney MM; Korn EL
Cancer J; 2019; 25(4):254-263. PubMed ID: 31335389
[TBL] [Abstract][Full Text] [Related]
5. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
Masuda M; Nakagawa R; Kondo T
Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
[TBL] [Abstract][Full Text] [Related]
7. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?
Morgan G; Aftimos P; Awada A
Curr Opin Oncol; 2016 Sep; 28(5):441-6. PubMed ID: 27428363
[TBL] [Abstract][Full Text] [Related]
8. Precision Oncology: Between Vaguely Right and Precisely Wrong.
Brock A; Huang S
Cancer Res; 2017 Dec; 77(23):6473-6479. PubMed ID: 29162615
[TBL] [Abstract][Full Text] [Related]
9. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
Baretti M; Azad NS
Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
[TBL] [Abstract][Full Text] [Related]
10. Precision oncology: the intention-to-treat analysis fallacy.
Sicklick JK; Kato S; Okamura R; Kurzrock R
Eur J Cancer; 2020 Jul; 133():25-28. PubMed ID: 32422506
[TBL] [Abstract][Full Text] [Related]
11. Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.
Arai RJ; Guindalini RSC; Llera AS; O'Connor JM; Muller B; Lema M; Freitas HC; Soria T; Delgado L; Landaverde D; Montenegro P; Riechelmann RP
Oncologist; 2019 Aug; 24(8):e709-e719. PubMed ID: 30910864
[TBL] [Abstract][Full Text] [Related]
12. [Precision oncology and molecular tumor boards].
Mack E; Horak P; Fröhling S; Neubauer A
Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
14. Precision medicine in oncology: what is it exactly and where are we?
Le Tourneau C; Kamal M; Bièche I
Per Med; 2018 Sep; 15(5):351-353. PubMed ID: 30260312
[No Abstract] [Full Text] [Related]
15. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.
Said R; Tsimberidou AM
Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
17. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
18. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
19. Integrating proteomics into precision oncology.
Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
[TBL] [Abstract][Full Text] [Related]
20. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]